Home / Catalogue/ Metabolic/ Survodutide

MetabolicIn StockSubQ injection

Survodutide

Acylated peptide · GLP-1/glucagon dual agonist · Synthetic

Half-life

~5-6d

After administration

Delivery Method

SubQ injection

Route of administration

Storage (Lyophilised)

12-24 months

2–8°C

Storage (Reconstituted)

4–6 weeks

Refrigerate at 2-8C

Known For

Dual GLP-1/Glucagon agonist (different mechanism to tirzepatide which is GLP-1/GIP). Being studied for obesity and NASH. The glucagon component may help with liver fat specifically.

Mechanism of Action

Dual GLP-1 + glucagon agonist — similar to retatrutide minus GIP. Glucagon adds liver fat reduction + thermogenesis.

Body vs. External Supply

🔴 Exogenous (replaces natural)

Brand / Trade Names

No brand name yet (Investigational — Boehringer Ingelheim) Phase 3 ongoing

Typical Research Dosage

Early research: titrate from 0.5mg → up to 4.8-6mg weekly. Protocol still being established in trials.

Vial Duration Guide

10mg vial: highly variable depending on dose. At 2mg/wk = 5 weeks.

Recommended Vial Size

★ 10mg (only size) At 2-4mg/wk, 10mg lasts 2.5-5 weeks ✓. Fits within shelf life at most doses.

Time to Effects

EARLY: 2-4 weeks FULL: 24+ weeks Limited human data. Expected timeline similar to other GLP-1 agonists but with potentially faster liver fat reduction due to glucagon component. Week 2-4: Appetite suppression, early weight loss. Week 12-24: Significant fat loss and metabolic improvements. Minimum commitment: 12 weeks to assess.

Contraindications & Do Not Combine

• Do NOT combine with other GLP-1 agonists (Tirzepatide, Retatrutide, Semaglutide) • Same-class stacking = dangerous GI and metabolic side effects

Common Side Effects

Nausea (38%), diarrhoea (21%), vomiting (18%), decreased appetite (11%)

Drug Interactions

Expected similar to GLP-1 class. Glucagon component may affect hepatic drug metabolism.

Reversibility

Limited data — still investigational. Expected weight regain off treatment.

Key Peer-Reviewed References

All studies are published in indexed journals unless otherwise noted.

• Blüher et al. (2024) Phase 2 Trial. NEJM 391:1616-26. DOI: 10.1056/NEJMoa2403838 • Phase 3 SYNCHRONIZE program ongoing (Boehringer Ingelheim) • NOT YET FDA APPROVED • ClinicalTrials.gov: NCT06058364

Research Disclaimer

Almost all data is preclinical (animal or in-vitro). No large-scale randomised controlled human trials are available for most compounds on this catalogue. This information is provided for research reference only.

Storage Requirements

Clinical supply — 2-8°C

State	Condition	Duration
Lyophilised (sealed)	2–8°C	12-24 months
Reconstituted	2-8C	4–6 weeks

Reconstitution Note

Reconstitute with bacteriostatic water (BAC water). Do not shake vigorously -- swirl gently to dissolve. Inject BAC water slowly down the side of the vial to avoid denaturing the peptide.

Video Resources

Survodutide discussed by researchers & practitioners

Independent educational content from researchers, clinicians, and science communicators. Not affiliated with Pepnerd — provided as supplementary reading.

Educational resources only. The videos above are independent third-party content from researchers, clinicians, and science communicators. Pepnerd is not affiliated with any of these creators and does not endorse or make any claims based on their content. All products are sold strictly for in-vitro scientific research.

Select Vial Size

$350.00 per vial

Submit Your Test Results →

Quick Reference

Half-life	~5-6 days
Delivery	SubQ injection
Typical dose	0.5mg
Storage (lyoph.)	2–8°C
Storage (recon.)	4–6 weeks
Endogenous?	Exogenous (replaces natural)
Suppression	None known
WADA	Not listed — investigational
FDA status	Phase 2/3 trials